Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chula Vista, California 91910


Purpose:

This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.


Criteria:

Inclusion Criteria: - Diagnosis of prostate cancer. - Rising PSA while on hormonal therapy or following surgical castration. - Documented evidence of metastatic disease. Exclusion Criteria: - Have received cytotoxic chemotherapy. - Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.


NCT ID:

NCT00036543


Primary Contact:

Study Director
Darryl Sleep, M.D.
Abbott


Backup Contact:

N/A


Location Contact:

Chula Vista, California 91910
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.